Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Jul 3, 2022
Date Accepted: Jan 10, 2023

The final, peer-reviewed published version of this preprint can be found here:

Translating and Adapting the DISCERN Instrument Into a Simplified Chinese Version and Validating Its Reliability: Development and Usability Study

Shan Y, Xing Z, Dong Z, Ji M, Wang D, Cao X

Translating and Adapting the DISCERN Instrument Into a Simplified Chinese Version and Validating Its Reliability: Development and Usability Study

J Med Internet Res 2023;25:e40733

DOI: 10.2196/40733

PMID: 36729573

PMCID: 9936359

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Development of the Simplified-Chinese Version of DISCERN: Translation, Adaptation, and Validation

  • Yi Shan; 
  • Zhaoquan Xing; 
  • Zhaogang Dong; 
  • Meng Ji; 
  • Ding Wang; 
  • Xiangting Cao

ABSTRACT

Background:

There is a wide variation in the quality of information available to patients who seek information on the treatment of the diseases afflicting them. To help patients find clear and accessible information, many scales have been designed to evaluate the quality of health information. These instruments are primarily in English. Few of them have been translated and adapted into simplified-Chinese tools for health information assessment in China.

Objective:

This study aimed to translate and adapt DISCERN into the first simplified-Chinese version and to validate the psychometric properties of this newly-developed scale for judging the quality of patient-oriented health information on treatment choices in China.

Methods:

First we translated DICERN into simplified-Chinese using rigorous guidelines for translation and validation studies. We tested translation equivalence and measured the content validity index. Then we presented the simplified-Chinese instrument to 2 health educators and asked them to use it to assess the quality of 15 lung cancer-related materials. Subsequently, we invited another 3 health educators to rate 1 lung cancer-related brochure. Finally, we calculated Cohen’s kappa coefficient and Cronbach’s alpha to determine the reliability of the new instrument.

Results:

We decided on the final version of the simplified-Chinese DISCERN (C-DISCERN) after resolving all problems in translation, adaptation, and content validation. The C-DISCERN was valid and reliable: (1) the content validity index was .98 (47/48) in clarity and .94 (45/48) in relevance; (2) Cohen’s kappa coefficient for interrater agreement was .53 (p<.05); and (3) Cronbach’s alpha for internal consistency was .93 (confidence interval=95%) for the whole translated scale.

Conclusions:

The C-DISCERN is the first simplified-Chinese version of the DISCERN instrument. Its validity and reliability has been attested for assessing the quality of patient-targeted information for treatment choices.


 Citation

Please cite as:

Shan Y, Xing Z, Dong Z, Ji M, Wang D, Cao X

Translating and Adapting the DISCERN Instrument Into a Simplified Chinese Version and Validating Its Reliability: Development and Usability Study

J Med Internet Res 2023;25:e40733

DOI: 10.2196/40733

PMID: 36729573

PMCID: 9936359

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.